Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.94
    -0.04 (-2.27%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 4:34 PM ET

    CytomX Therapeutics Inc (CTMX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CytomX Therapeutics (CTMX) has a market cap of $444.73M and an enterprise value of $414.63M. It kept -608.98% of revenue as net income over the last 12 months. Its share count is up 32.79% from a year earlier.

    Total Valuation

    Enterprise value is 6.77% below the market cap, as cash exceeds debt.

    Market Cap$444.73M
    Enterprise Value$414.63M
    Latest price (Nov 17, 2026)$1.94

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.08% in the quarter ended Sep 30, 2026 and grew 60.46% a year over 2 years.

    Shares Outstanding219.11M
    Shares Change (YoY)+32.79%
    Shares Change (QoQ)+0.08%
    Share Count Growth (2Y CAGR)+60.46%

    Valuation Ratios

    Sales and book value multiples are 30.3x and 1.5x. Its year-end P/S ranged from 0.6x to 26.5x from 2016 to 2025.

    P/S Ratio30.3x
    Forward P/S20.3x
    P/B Ratio1.5x
    P/TBV Ratio1.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 50.00% over 52 weeks and trades 22.40% below its 50-day average.

    Beta (1Y)1.53
    52-Week Change-50.00%
    1-Month Change-17.09%
    3-Month Change-45.66%
    6-Month Change-46.70%
    5-Year Change-60.54%
    10-Year Change-79.24%
    Total Return (1Y)-50.00%
    Total Return (3Y CAGR)+13.69%
    Total Return (5Y CAGR)-23.13%
    Return vs SPY (1Y)-58.55%
    Max Drawdown (1Y)-71.26%
    Max Drawdown (3Y)-91.59%
    Sharpe Ratio (1Y)-0.78
    Correlation with SPY (1Y)0.26
    50-Day Average$2.50
    200-Day Average$3.67
    52-Week Range$1.90 to $8.21
    RSI (14 Days)36.2
    Average Volume (20 Days)5.19M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.82x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio7.82x
    Quick Ratio7.82x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -32.76% over the last 12 months, against a 5-year average of -22.56%.

    Return on Equity (ROE)-29.98%
    Return on Assets (ROA)-23.42%
    Return on Invested Capital (ROIC)-32.76%
    ROA (5Y Average)-11.50%
    ROIC (5Y Average)-22.56%
    Asset Turnover0.05x
    Receivables Turnover0.74x

    Scores

    CTMX has an Altman Z-Score of 0.44, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.44
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $14.03M over the last 12 months is down 87.66% from the 12 months before.

    Revenue$14.03M
    Revenue Growth (YoY)-87.66%
    Gross Profit$14.03M
    Operating Income-$94.89M
    Pretax Income-$85.19M
    Net Income-$85.42M
    Reported EPS (TTM)-$0.50

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 78.12% of the $364.68M in total assets.

    Cash and Equivalents$33.96M
    Total Debt$3.86M
    Net Cash$30.10M
    Net Cash Per Share$0.14
    Working Capital$310.52M
    Shareholder Equity$284.89M
    Book Value Per Share$1.30
    Tangible Book Value$283.61M
    Tangible Book Per Share$1.29
    Total Assets$364.68M
    Total Liabilities$79.79M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$50.21M
    FCF Per Share-$0.23
    Depreciation and Amortization$5.17M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -676.45%.

    Gross Margin100.00%
    Operating Margin-676.45%
    Pretax Margin-607.31%
    Net Margin-608.98%
    Net Margin (5Y Average)-99.53%

    Growth

    Revenue grew 12.75% a year over 3 years.

    Revenue Growth (3Y CAGR)+12.75%
    Revenue Growth (5Y CAGR)+2.18%

    Revenue and profit by year

    Dividends and Yields

    CTMX does not pay a dividend.

    Buyback Yield-59.22%
    Shareholder Yield-59.22%

    Peer Position

    Against 5 similar companies, CTMX has the highest P/S.

    P/S Ratio30.3x vs 1.7x median
    ROIC-32.76% vs -29.19% median
    Revenue Growth (Trailing 4 Quarters, YoY)-87.66% vs -23.76% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -41.48% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-41.48%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CTMX

    What is CTMX's market cap?

    CytomX Therapeutics has a market cap of $444.73M. Its enterprise value, which adds debt and subtracts cash, is $414.63M.

    How many shares of CTMX are outstanding?

    CytomX Therapeutics has 219.11M shares outstanding. The count is up 32.79% from a year earlier.

    Does CTMX pay a dividend?

    No. CytomX Therapeutics does not pay a dividend.

    How much debt does CTMX have?

    CytomX Therapeutics has $3.86M of total debt and $33.96M of cash and equivalents, a net cash position of $30.10M.